The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity

References

• Aleksunes LM, Augustine LM, Cherrington NJ, Manautou JE. (2007). Influence of acetaminophen vehicle on regulation of transporter gene expression during hepatotoxicity. J Toxicol Environ Health A 70:1870–2
   PubMed Web of Science ®Google Scholar
• Aleo MD, Luo Y, Swiss R, et al. (2014). Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60:1015–22
   PubMed Web of Science ®Google Scholar
• Boyer JL. (2009). It's all about bile. Hepatology 49:711–23
   PubMed Web of Science ®Google Scholar
• Byrne JA, Strautnieks SS, Mieli-Vergani G, et al. (2002). The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123:1649–58
   PubMed Web of Science ®Google Scholar
• Chowdhury A, Santra A, Bhattacharjee K, et al. (2006). Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 45:117–26
   PubMed Web of Science ®Google Scholar
• Cuperus FJ, Claudel T, Gautherot J, et al. (2014). The role of canalicular ABC transporters in cholestasis. Drug Metab Dispos 42:546–60
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M, et al. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–31
   PubMed Web of Science ®Google Scholar
• Fickert P, Stieger B. (2014). Molecular pathogenesis of chronic cholestatic liver disease: impact on novel therapeutic approaches. Mol Aspects Med 37:1–2
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Cruz A, Ferrin G, et al. (2011). Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. J Hepatobiliary Pancreat Sci 18:740–50
   PubMed Web of Science ®Google Scholar
• Ichai P, Saliba F, Antoun F, et al. (2010). Acute liver failure due to antitubercular therapy: strategy for antitubercular treatment before and after liver transplantation. Liver Transpl 16:1136–46
   PubMed Web of Science ®Google Scholar
• Jasmer RM, Saukkonen JJ, Blumberg HM, et al. (2002). Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 137:640–7
   PubMed Web of Science ®Google Scholar
• Jigorel E, Le Vee M, Boursier-Neyret C, et al. (2006). Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756–63
   PubMed Web of Science ®Google Scholar
• Kimmoun E, Samuel D. (2002). Antituberculous drugs in patients with chronic liver disease. J Gastroenterol Hepatol 17:S408–12
   PubMedGoogle Scholar
• Lee WM. (2003). Drug-induced hepatotoxicity. N Engl J Med 349:474–85
   PubMed Web of Science ®Google Scholar
• Leslie EM, Watkins PB, Kim RB, Brouwer KL. (2007). Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170–8
   PubMed Web of Science ®Google Scholar
• Lian Y, Zhao J, Xu P, et al. (2013). Protective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice. PLoS One 8:e72058
   PubMed Web of Science ®Google Scholar
• Lickteig AJ, Slitt AL, Arkan MC, et al. (2007). Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab Dispos 35:402–9
   PubMed Web of Science ®Google Scholar
• Luo L, Schomaker S, Houle C, et al. (2014). Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci 137:12–25
   PubMed Web of Science ®Google Scholar
• Maher JM, Cherrington NJ, Slitt AL, Klaassen CD. (2006). Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. Life Sci 78:2219–25
   PubMed Web of Science ®Google Scholar
• Marion TL, Leslie EM, Brouwer KL. (2007). Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4:911–18
   PubMed Web of Science ®Google Scholar
• Mcrae MP, Lowe CM, Tian X, et al. (2006). Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318:1068–75
   PubMed Web of Science ®Google Scholar
• Naguib YM, Azmy RM, Samaka RM, Salem MF. (2014). Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress in acetaminophen-induced hepato-renal injury. BMC Complement Altern Med 14:494
   PubMed Web of Science ®Google Scholar
• Senousy BE, Belal SI, Draganov PV. (2010). Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol 7:543–56
   PubMed Web of Science ®Google Scholar
• Sokol RJ, Devereaux M, Dahl R, Gumpricht E. (2006). “Let there be bile” – understanding hepatic injury in cholestasis. J Pediatr Gastroenterol Nutr 43:S4–9
   PubMed Web of Science ®Google Scholar
• Steele MA, Burk RF, Desprez RM. (1991). Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 99:465–71
   PubMed Web of Science ®Google Scholar
• Stieger B. (2011). The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 201:205–59
   PubMedGoogle Scholar
• Stieger B, Fattinger K, Madon J, et al. (2000). Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422–30
   PubMed Web of Science ®Google Scholar
• Wolf KK, Vora S, Webster LO, et al. (2010). Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. Toxicol In Vitro 24:297–309
   PubMed Web of Science ®Google Scholar
• Wu ZT, Qi XM, Sheng JJ, et al. (2014). Timosaponin A3 induces hepatotoxicity in rats through inducing oxidative stress and down-regulating bile acid transporters. Acta Pharmacol Sin 35:1188–98
   PubMed Web of Science ®Google Scholar
• Xing T, Chen J, Zhang G. (1997). [Clinical and pathological analysis of liver injury resulting from rifampin and isoniazid]. Zhonghua Jie He He Hu Xi Za Zhi 20:33–5
   PubMedGoogle Scholar
• Yamazaki M, Miyake M, Sato H, et al. (2013). Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol 268:79–89
   PubMed Web of Science ®Google Scholar
• Yang L, Xiong A, He Y, et al. (2008). Bile Acids Metabonomic Study on the CCl4- and α-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography−mass spectrometry. Chem Res Toxicol 21:2280–8
   PubMed Web of Science ®Google Scholar
• Yew WW, Leung CC. (2007). Antituberculosis drugs and hepatotoxicity. Am J Respir Crit Care Med 175: 858; author reply 858–9
   PubMed Web of Science ®Google Scholar
• Yuhas Y, Berent E, Ashkenazi S. (2011). Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells. Antimicrob Agents Chemother 55:5541–6
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304
   PubMed Web of Science ®Google Scholar
• Zollner G, Trauner M. (2008). Mechanisms of cholestasis. Clin Liver Dis 12:1–26
   PubMed Web of Science ®Google Scholar